For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue under licensing agreements | 0 | 925 | ||
| Research and development expenses | 75,011 | 60,917 | ||
| General and administrative expenses | 28,317 | 22,613 | ||
| Total operating expenses | 103,328 | 83,530 | ||
| Loss from operations | -103,328 | -82,605 | ||
| Interest income | 11,547 | 8,467 | ||
| Interest expense | 5 | 12 | ||
| Other income | 1,665 | 574 | ||
| Other expense | 230 | 1,568 | ||
| Net loss | -90,351 | -75,144 | ||
| Basic EPS | -4.24 | -4.28 | ||
| Diluted EPS | -4.24 | -4.28 | ||
| Basic Average Shares | 21,326,283 | 17,567,082 | ||
| Diluted Average Shares | 21,326,283 | 17,567,082 | ||
Neurogene Inc. (NGNE)
Neurogene Inc. (NGNE)